12.10.25 -- 2025 Review: Customer Service As Important As Capacity And Capability

To safeguard the consistent delivery of essential therapies to patients around the world, biopharmaceutical companies, alongside their CDMO partners, are rethinking traditional supply models.

From AI to adaptive trial designs, the industry is undergoing a transformation that is equal parts scientific and strategic. Learn about the innovations poised to redefine pipelines.

Understand the basic principles of analytical development for cGMP assays and the assays that are generally relevant to major biopharmaceutical modalities.

This segment of the Outsourced Pharma Live event, “Small Molecule Outsourcing: Getting Timelines, Tech Transfer and Analytics Right,” addresses how to balance trusting a CDMO as a subject-matter expert with maintaining sufficient oversight through clear KPIs, targeted on-site presence at critical milestones, and a partnership mindset where both sides work to enable each other’s success and demonstrate ongoing trustworthiness.

Solvents account for the majority of the environmental impact in chemical synthesis. Consider adopting safer alternatives and implementing reuse strategies to reduce waste, emissions, and toxicity.

Discover a screening process to quickly assess HME feasibility that yields more accurate predictions for API loading and degradation while saving material and time compared to traditional approaches.

When developing a nasal delivery program, a partner with experience in development and manufacturing techniques who can see a program through small-scale clinical to commercial supply is crucial.

Among oral dosage forms, softgel capsules stand out as a versatile and high-performance option — offering superior delivery characteristics, consumer appeal, and brand differentiation.

Partnering with a CDMO that offers comprehensive and robust E&L studies can help facilitate a smooth product launch by ensuring minimal impact from impurities, all while mitigating risks.

Lonza's SimpliFiH^® Solutions offering is designed to simplify and accelerate the development pathway, even for APIs with challenging properties, such as low aqueous solubility and poor bioavailability.

Enhance the bioavailability of poorly soluble drugs and outperform traditional MBP methods by producing dense amorphous dispersions in pharmacokinetics and dissolution.

Overcome clinical transition challenges with integrated services, including study design, expert regulatory support, robust recruitment, and flexible manufacturing.

Get the details on our facilities, capabilities from concept through commercialization, Category 3A/3B potency capabilities, regulatory approvals and registrations, and specializations.

Accelerate the development of small molecules and biologics with integrated CDMO services. Access specialized capabilities from process development to GMP manufacturing and sterile fill/finish.

Consider how microencapsulation by coacervation can transform your formulations, ensuring smooth mouthfeel, effective taste masking, and customized release profiles.

Our network currently spans across nine manufacturing sites in five countries and can support discovery, preclinical, clinical, and commercial programs for New Chemical Entities (NCEs).